This week in drug discovery (16-20 June)
News round-up for 16-20 June by DDW Senior Digital Content Editor Diana Spencer.
In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there have been several significant developments in oncology drug discovery, including new therapy options for some difficult to treat cancers.
The top stories:
Cancer plasticity atlas will help predict drug response
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich has announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies.
New approach shows promise in aggressive breast cancers
A clinical trial for early-stage breast cancer patients with BRCA gene mutations has reported 100% survival after three years.
Drug combination treats B-cell lymphoma
Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug.
Scientists uncover mechanism behind drug resistance in bowel cancer
Scientists at The Institute of Cancer Research (ICR), London, have discovered what may cause some treatments to stop working in people living with bowel cancer.
Adding immunotherapy improves survival rates in anal cancer
Treating advanced anal cancer patients with both immunotherapy and chemotherapy improved overall survival by an average of six months, according to a study led by The Royal Marsden NHS Foundation Trust.
